Form 6-K Ascendis Pharma A/S For: Mar 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip stocks' gains offset Middle East jitters
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil eases as investors assess US-Iran peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Ascendis Pharma (ASND) PT Raised to $185 at Cantor Fitzgerald
March 4, 2019 10:33 AM ESTCantor Fitzgerald analyst Alethia Young raised the price target on Ascendis Pharma (NASDAQ: ASND) to $185.00 (from $100.00) while maintaining a Overweight rating.
... More